Beta Drugs Limited

BETA

INE351Y01019

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:46 2024-04-26 am EDT			5-day change	1st Jan Change
1,306 ^INR	-2.87%		-6.59%	-11.13%

2023	Beta Drugs Limited Reports Earnings Results for the Half Year Ended September 30, 2023	CI
2023	Beta Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2023	CI

Beta Drugs Limited Gets DCGI Approval for Its New Drug KABONIB

April 11, 2022 at 11:25 pm EDT

Beta Drugs Ltd. (BDL) has developed an in-house Cabozantinib under the brand name KABONIB and received approval from the Drug Controller General of India (DCGI) to manufacture its API & formulation.

Latest news about Beta Drugs Limited

Beta Drugs Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 07	CI
Beta Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-08	CI
Beta Drugs Limited Reports Earnings Results for the Half Year Ended September 30, 2022	22-10-27	CI
Beta Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-04-26	CI
Beta Drugs Limited Gets DCGI Approval for Its New Drug KABONIB	22-04-11	CI
Beta Drugs Limited Reports Earnings Results for the Half Year Ended September 30, 2021	21-11-10	CI
Beta Drugs Ltd Receives WHO- GMP Approval for Its API Plant	21-07-19	CI
Beta Drugs Limited Announces Demise of Vijvay Kumar Batra, Managing Director and Announces Executive Promotions	21-01-27	CI
Beta Drugs Limited Announces Demise of Vijvay Kumar Batra, Board Chairman; Promotes Rahul Batra to the Board Chairman	21-01-27	CI
Beta Drugs Limited Appoints Mr. Varun Batra as Joint Managing Director of the Company	21-01-27	CI
Beta Drugs Limited Reports Earnings Results for the Half Year Ended September 30, 2020	20-11-12	CI
1,732,000 Equity Shares of Beta Drugs Limited are subject to a Lock-Up Agreement Ending on 15-OCT-2020.	20-10-14	CI
Beta Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2020	20-05-29	CI
Beta Drugs Ltd. Receives Registration Certificates for 20 Injectables from Ministry of Health Uzbekistan	20-04-27	CI
Beta Drugs Limited acquired Adley Lab Ltd from group of shareholders for INR 45 million.	19-10-24	CI
Beta Drugs Limited Reports Earnings Results for the Half Year Ended September 30, 2019	19-10-22	CI
Beta Drugs Limited agreed to acquire Adley Lab Ltd from a group of shareholders for INR 45.04 million	19-05-29	CI
Beta Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2019	19-05-12	CI
4,621,500 Equity Shares of Beta Drugs Limited are subject to a Lock-Up Agreement Ending on 15-OCT-2018.	18-10-14	CI
Beta Drugs Limited has completed an IPO in the amount of INR 195.16 million.	17-10-11	CI
Beta Drugs Limited has filed an IPO.	17-08-28	CI

Beta Drugs Limited is an India-based company, which is engaged in manufacturing of the wide range of anti-cancer drugs in India. The Company operates through manufacturing of Oncology medicines segment. The Company offers a portfolio consisting of approximately 50 products catering to various oncology diseases, including breast, lung, head, and neck, colorectal, ovarian, gastric, brain, testicular renal, prostate, leukemia, lymphoma, myeloma, supportive. The Companyâs oncology portfolio includes various brands, such as AB-PACLI, ADBIRON, ADCARB, ADCIST, Adlante, ADLEAP, ADMIDE, ADOXI, CAPAD, ARBAZ, FISTENT, BUSFAN, Triodelta and others. The Company's subsidiaries include Adley Lab Limited, Adley Formulations Private Limited.

Sector

Pharmaceuticals

Calendar

2024-10-22 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BETA DRUGS LIMITED	-11.13%	151M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B